Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 16/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21888318 | 0.97 | CYP1B1 (0.47) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL75348 | 0.91 | CYP1B1 (0.51) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL21888320 | 0.85 | CYP1B1 (0.47) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL22727866 | 0.85 | CYP1B1 (0.47) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL21888684 | 0.84 | CYP1B1 (0.46) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL14680338 | 0.82 | CYP1B1 (0.49) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL15457926 | 0.82 | CYP1A2 (0.58) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL77179 | 0.78 | CYP1B1 (0.61) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL29583035 | 0.78 | CYP1B1 (0.61) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 | |
| SCHEMBL13002347 | 0.77 | CYP1A2 (0.53) | CYP1B1CYP1A2ALDH1A1POLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8963813-B2 | Organic compound and organic light emitting device having the same | CANON KABUSHIKI KAISHA (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8963813-B2 | Organic compound and organic light emitting device having the same | CANON KABUSHIKI KAISHA (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130033416-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-02-07 | — | — | US | disclosed |
| US-20130033416-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130033416-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE SAME | TRPA1, OCIAD1, BMP2 | CYP1B1 68/4885CYP1A2 107/4885ALDH1A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.